| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/JNC.13248 |
| P698 | PubMed publication ID | 26183127 |
| P2093 | author name string | Yan Yang | |
| Gang Yuan | |||
| De-Lin Ma | |||
| Wei-Jie Xu | |||
| Fu-Qiong Chen | |||
| Wen-Zhu Yue | |||
| P2860 | cites work | GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides | Q28205921 |
| Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. | Q51338027 | ||
| Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease | Q29617286 | ||
| Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice | Q30419141 | ||
| The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes | Q33826388 | ||
| Microarray analysis of the astrocyte transcriptome in the aging brain: relationship to Alzheimer's pathology and APOE genotype. | Q33943081 | ||
| Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. | Q34338701 | ||
| Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain | Q34452590 | ||
| Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model | Q34639384 | ||
| Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. | Q34655623 | ||
| Tau in Alzheimer disease and related tauopathies | Q34953869 | ||
| Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial | Q35679839 | ||
| Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes | Q35794263 | ||
| Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline | Q35858095 | ||
| Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis | Q35960169 | ||
| Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease | Q36012200 | ||
| Insulin signaling and insulin resistance | Q36806238 | ||
| History of medically treated diabetes and risk of Alzheimer disease in a nationwide case-control study | Q36942194 | ||
| Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease | Q37382673 | ||
| Targeting tau protein in Alzheimer's disease | Q37744878 | ||
| Effect of intranasal insulin on cognitive function: a systematic review | Q37967672 | ||
| Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection | Q38039489 | ||
| Overlapped metabolic and therapeutic links between Alzheimer and diabetes. | Q38046539 | ||
| Alzheimer disease and diabetes mellitus: do they have anything in common? | Q38102765 | ||
| Molecular links between Alzheimer's disease and diabetes mellitus | Q38122603 | ||
| Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? | Q38192319 | ||
| Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress | Q39083326 | ||
| Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice | Q42715172 | ||
| Neurobehavioral deficits in db/db diabetic mice | Q42736763 | ||
| Diet-induced obesity induces endoplasmic reticulum stress and insulin resistance in the amygdala of rats | Q42904879 | ||
| Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight | Q42936904 | ||
| Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. | Q42950655 | ||
| Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. | Q46396191 | ||
| Detection of beta-endorphin in the cerebrospinal fluid after intrastriatal microinjection into the rat brain | Q46436795 | ||
| A biochemical and functional characterization of diet-induced brain insulin resistance | Q46526769 | ||
| Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db/db mice | Q46673962 | ||
| Age-dependent increases in tau phosphorylation in the brains of type 2 diabetic rats correlate with a reduced expression of p62. | Q47881193 | ||
| Hyperinsulinemia in rats causes impairment of spatial memory and learning with defects in hippocampal synaptic plasticity by involvement of postsynaptic mechanisms | Q48181763 | ||
| Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease | Q48270990 | ||
| Brain insulin resistance accelerates Aβ fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes | Q48703627 | ||
| Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone. | Q48912299 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liraglutide | Q2526479 |
| P304 | page(s) | 301-308 | |
| P577 | publication date | 2015-07-16 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice. | |
| P478 | volume | 135 |
| Q39270980 | A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies |
| Q90679431 | Antidiabetic therapies and Alzheimer disease |
| Q38994655 | Dynamics of diabetes and obesity: Epidemiological perspective |
| Q47217002 | Gelidium elegans Extract Ameliorates Type 2 Diabetes via Regulation of MAPK and PI3K/Akt Signaling |
| Q47161453 | Laminarin counteracts diet-induced obesity associated with glucagon-like peptide-1 secretion |
| Q64088518 | Liraglutide and its Neuroprotective Properties-Focus on Possible Biochemical Mechanisms in Alzheimer's Disease and Cerebral Ischemic Events |
| Q38668948 | Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases |
| Q58795095 | Pin1 Modulation in Physiological Status and Neurodegeneration. Any Contribution to the Pathogenesis of Type 3 Diabetes? |
| Q59812434 | Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function |
| Q38926789 | Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes |
| Q26768527 | The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action |
| Q38823805 | Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia |
| Q36905790 | Type 2 diabetes-induced neuronal pathology in the piriform cortex of the rat is reversed by the GLP-1 receptor agonist exendin-4. |
Search more.